ABCR  Vol.9 No.3 , July 2020
Cardiac Safety with High Cumulative Dose of Pegylated Liposomal Doxorubicin in Patients with Metastatic Breast Cancer Previously Treated with Conventional Anthracyclines
Abstract: Introduction: The treatment of metastatic breast cancer (MBC) is still challenging. Many studies documented the efficacy of pegylated liposomal doxorubicin (PLD) in patients with MBC, but there is a limited data about the cardiac safety with high cumulative dose (HCD) of PLD. Aim of the work: We conducted this trial to outline the cardiac safety of HCD of PLD in patients with MBC who previously received conventional anthracyclines. Methods: During the period of nine years (January 2011 to December 2019). We extracted the data of the patients with MBC receiving PLD at Medical Oncology Department, South Egypt Cancer Institute, Assiut University. These included patients’ demographics and therapeutic data including the full data of PLD, prior conventional anthracyclines, prior trastuzumab, and prior radiotherapy. Also, data about comorbidities as well as cardiac and other toxicities of PLD were obtained. The data was analysed using SPSS v. 21. Results: For all 81 eligible patients, the mean age was 43.9 years (±standard deviation (SD) 13.2). The mean cumulative dose of PLD was 378.4 mg/m2 (± SD of 250.2) and a range of 100 - 1200 mg/m2. About thirty-one (38.3%) patients received high cumulative dose (400 mg/m2 or more), while the remaining 50 patients did not. The decline in left ventricular ejection fraction (LVEF) was relatively rare; and of low grade. Grade 2 decline in LVEF occurred in only two patients who received high cumulative dose of PLD, and only one patient who did not reach HCD (p = 0.555). Grade 3 or 4 decline in LVEF did not occur in patients either with or without HCD. Regarding other toxicities, there was a significant increase in incidence of all grades palmar plantar erythrodysesthesia (PPE) in patients who received HCD of PLD when compared to those who did not reach the HCD (38.7% versus 16% respectively; p = 0.021). Conclusion: Our study concluded that the use of PLD seems to be a justified agent in the treatment of MBC who previously treated by conventional anthracyclines in the adjuvant, metastatic or both settings, even in patients reaching the cumulative dose of conventional anthracycline.
Cite this paper: Refaat, A. , Mohamed, D. , Ali, E. and Khallaf, S. (2020) Cardiac Safety with High Cumulative Dose of Pegylated Liposomal Doxorubicin in Patients with Metastatic Breast Cancer Previously Treated with Conventional Anthracyclines. Advances in Breast Cancer Research, 9, 55-65. doi: 10.4236/abcr.2020.93005.

[1]   Ferlay, J., Shin, H.R., Bray, F., Forman, D., Mathers, C. and Parkin, D.M. (2010) Estimates of Worldwide Burden of Cancer in 2008: GLOBOCAN 2008. International Journal of Cancer, 127, 2893-2917.

[2]   Iqbal, J., Ginsburg, O., Rochon, P.A., Sun, P. and Narod, S.A. (2015) Differences in Breast Cancer Stage at Diagnosis and Cancer-Specific Survival by Race and Ethnicity in the United States. The Journal of the American Medical Association, 313, 165-173.

[3]   Hayes, D. (2009) An Overview of Treatment for Locally Advanced Recurrent, and Metastatic Breast Cancer. UpToDate, 9, 66-72.

[4]   Gralow, J.R. (2005) Optimizing the Treatment of Metastatic Breast Cancer. Breast Cancer Research and Treatment, 89, S9-S15.

[5]   Al-Batran, S.E., Bischoff, J., von Minckwitz, G., Atmaca, A., Kleeberg, U., Meuthen, I., Morack, G., Lerbs, W., Hecker, D., Sehouli, J., Knuth, A. and Jager, E. (2006) The Clinical Benefit of Pegylated Liposomal Doxorubicin in Patients with Metastatic Breast Cancer Previously Treated with Conventional Anthracyclines: A Multicentre Phase II Trial. British Journal of Cancer, 94, 1615-1620.

[6]   Rafiyath, S.M., Rasul, M., Lee, B., Wei, G., Lamba, G. and Liu, D. (2012) Comparison of Safety and Toxicity of Liposomal Doxorubicin vs. Conventional Anthracyclines: A Meta-Analysis. Experimental Hematology & Oncology, 1, 10.

[7]   McGowan, J.V., Chung, R., Maulik, A., Piotrowska, I., Walker, J.M. and Yellon, D.M. (2017) Anthracycline Chemotherapy and Cardiotoxicity. Cardiovascular Drugs and Therapy, 31, 63-75.

[8]   Xing, M., Yan, F., Yu, S. and Shen, P. (2015) Efficacy and Cardiotoxicity of Liposomal Doxorubicin-Based Chemotherapy in Advanced Breast Cancer: A Meta-Analysis of Ten Randomized Controlled Trials. PLoS ONE, 10, e0133569.

[9]   Simunek, T., Sterba, M., Popelova, O., Adamcova, M., Hrdina, R. and Gersl, V. (2009) Anthracycline-Induced Cardiotoxicity: Overview of Studies Examining the Roles of Oxidative Stress and Free Cellular Iron. Pharmacological Reports, 61, 154-171.

[10]   Rivera, E. (2003) Liposomal Anthracyclines in Metastatic Breast Cancer: Clinical Update. Oncologist, 8, 3-9.

[11]   Harbeck, N., Saupe, S., Jager, E., Schmidt, M., Kreienberg, R., Müller, L., Otremba, B.J., Waldenmaier, D., Dorn, J., Warm, M., Scholz, M., Untch, M., de Wit, M., Barinoff, J., Lück, H.J., Harter, P., Augustin, D., Harnett, P., Beckmann, M.W. and Al-Batran, S.E. (2017) A Randomized Phase III Study Evaluating Pegylated Liposomal Doxorubicin versus Capecitabine as First-Line Therapy for Metastatic Breast Cancer: Results of the PELICAN Study. Breast Cancer Research and Treatment, 161, 63-72.

[12]   Kesterson, J.P., Odunsi, K. and Lele, S. (2010) High Cumulative Doses of Pegylated Liposomal Doxorubicin Are Not Associated with Cardiac Toxicity in Patients with Gynecologic Malignancies. Chemotherapy, 56, 108-111.


[14]   IBM Corp Released (2013) IBM SPSS Statistics for Windows. Version 22.0. IBM, Armonk, NY.

[15]   Keller, A.M., Mennel, R.G., Georgoulias, V.A., Nabholtz, J.M., Erazo, A., Lluch, A., Vogel, C.L., Kaufmann, M., von Minckwitz, G., Henderson, I.C., Mellars, L., Alland, L. and Tendler, C. (2004) Randomized Phase III Trial of Pegylated Liposomal Doxorubicin versus Vinorelbine or Mitomycin C plus Vinblastine in Women with Taxane-Refractory Advanced Breast Cancer. Journal of Clinical Oncology, 22, 3893-901.

[16]   Fiegl, M., Mlineritsch, B., Hubalek, M., Bartsch, R., Pluschnig, U. and Steger, G.G. (2011) Single-Agent Pegylated Liposomal Doxorubicin (PLD) in the Treatment of Metastatic Breast Cancer: Results of an Austrian Observational Trial. BMC Cancer, 11, 373.

[17]   Mlineritsch, B., Mayer, P., Rass, C., Reiter, E., Russ, G., Vesenmayer, G., Oberaigner, W. and Hausmaninger, H. (2004) Phase II Study of Single-Agent Pegylated Liposomal Doxorubicin HCl (PLD) in Metastatic Breast Cancer after Firstline Treatment Failure. Onkologie, 27, 441-446.

[18]   Huober, J., Fett, W., Nusch, A., Neise, M., Schmidt, M., Wischnik, A., Gerhardt, S., Goehler, T., Lück, H.J. and Rost, A. (2010) A Multicentric Observational Trial of Pegylated Liposomal Doxorubicin for Metastatic Breast Cancer. BMC Cancer, 10, 2.

[19]   Coleman, R.E., Biganzoli, L., Canney, P., Dirix, L., Mauriac, L., Chollet, P., Batter, V., Ngalula-Kabanga, E., Dittrich, C. and Piccart, M. (2006) A Randomised Phase II Study of Two Different Schedules of Pegylated Liposomal Doxorubicin in Metastatic Breast Cancer (EORTC-10993). European Journal of Cancer, 42, 882-887.

[20]   Lorusso, D., Di Stefano, A., Carone, V., Fagotti, A., Pisconti, S. and Scambia, G. (2007) Pegylated Liposomal Doxorubicin-Related Palmar-Plantar Erythrodysesthesia (‘Hand-Foot’ Syndrome).

[21]   Perez, A.T., Domenech, G.H., Frankel, C. and Vogel, C.L. (2002) Pegylated Liposomal Doxorubicin (Doxil) for Metastatic Breast Cancer: The Cancer Research Network, Inc., Experience. Cancer Investigation, 20, 2-29.

[22]   Von Moos, R., Thuerlimann, B.J., Aapro, M., Rayson, D., Harrold, K., Sehouli, J., Scotte, F., Lorusso, D., Dummer, R., Lacouture, M.E., Lademann, J. and Hauschild, A. (2008) Pegylated Liposomal Doxorubicin-Associated Hand-Foot Syndrome: Recommendations of an International Panel of Experts. European Journal of Cancer, 44, 781-790.